ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Medicenna Therapeutics Corporation (QX)

Medicenna Therapeutics Corporation (QX) (MDNAF)

0.8725
-0.0375
( -4.12% )
Actualizado: 11:09:08

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
0.8725
Postura de Compra
0.87
Postura de Venta
0.875
Volume Operado de la Acción
50,581
0.8725 Rango del Día 0.908
0.303 Rango de 52 semanas 2.20
Capitalización de Mercado [m]
Precio Anterior
0.91
Precio de Apertura
0.908
Última hora de negociación
11:09:08
Volumen financiero
US$ 45,132
Precio Promedio Ponderado
0.892273
Volumen promedio (3 m)
126,280
Acciones en circulación
78,157,903
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-3.90
Beneficio por acción (BPA)
-0.33
turnover
-
Beneficio neto
-25.47M

Acerca de Medicenna Therapeutics Corporation (QX)

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
Sede
Toronto, Ontario, Can
Fundado
-
Medicenna Therapeutics Corporation (QX) is listed in the Biological Pds,ex Diagnstics sector of the OTCMarkets with ticker MDNAF. The last closing price for Medicenna Therapeutics (QX) was US$0.91. Over the last year, Medicenna Therapeutics (QX) shares have traded in a share price range of US$ 0.303 to US$ 2.20.

Medicenna Therapeutics (QX) currently has 78,157,903 shares in issue. The market capitalisation of Medicenna Therapeutics (QX) is US$71.12 million. Medicenna Therapeutics (QX) has a price to earnings ratio (PE ratio) of -3.90.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.1175-11.86868686870.991.00750.8598588200.94768344CS
4-0.2525-22.44444444441.1251.1750.8598753790.98617132CS
12-0.824-48.57058650161.69651.80.85981262801.23165207CS
26-0.7575-46.4723926381.631.940.85981014091.40239603CS
520.5538173.7684342640.31872.20.3031123801.36834426CS
156-3.7975-81.31691648824.674.670.1581069901.20082346CS
260-1.4975-63.18565400842.375.320.158943611.66549082CS

MDNAF - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Medicenna Therapeutics (QX)?
El precio actual de las acciones de Medicenna Therapeutics (QX) es US$ 0.8725
¿Cuántas acciones de Medicenna Therapeutics (QX) están en circulación?
Medicenna Therapeutics (QX) tiene 78,157,903 acciones en circulación
¿Cuál es la capitalización de mercado de Medicenna Therapeutics (QX)?
La capitalización de mercado de Medicenna Therapeutics (QX) es USD 71.12M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Medicenna Therapeutics (QX)?
Medicenna Therapeutics (QX) ha negociado en un rango de US$ 0.303 a US$ 2.20 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Medicenna Therapeutics (QX)?
El ratio precio/beneficio de Medicenna Therapeutics (QX) es -3.9
¿Cuál es la moneda de reporte de Medicenna Therapeutics (QX)?
Medicenna Therapeutics (QX) presenta sus resultados financieros en CAD
¿Cuál es el último beneficio anual de Medicenna Therapeutics (QX)?
El último beneficio anual de Medicenna Therapeutics (QX) es CAD -25.47M
¿Cuál es la dirección registrada de Medicenna Therapeutics (QX)?
La dirección registrada de Medicenna Therapeutics (QX) es 200 - 1920 YONGE STREET, TORONTO, ONTARIO, M4S 3E2
¿Cuál es la dirección del sitio web de Medicenna Therapeutics (QX)?
La dirección del sitio web de Medicenna Therapeutics (QX) es www.medicenna.com
¿En qué sector industrial opera Medicenna Therapeutics (QX)?
Medicenna Therapeutics (QX) opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
AAGRAfrican Agriculture Holdings Inc (CE)
US$ 0.008
(799,900.00%)
400
NBDRNo Borders Inc (CE)
US$ 0.0001
(9,900.00%)
15k
GRLFGreen Leaf Innovations Inc (PK)
US$ 0.0001
(9,900.00%)
106.59M
TMPOQTempo Automation Holdings Inc (CE)
US$ 0.0001
(9,900.00%)
100
TTCFQTattooed Chef Inc (CE)
US$ 0.0001
(9,900.00%)
726
FONUFONU2 Inc (PK)
US$ 0.000001
(-99.00%)
30k
BRGOBergio International Inc (PK)
US$ 0.000001
(-99.00%)
1.5M
NEOMNeoMedia Technologies Inc (CE)
US$ 0.000001
(-99.00%)
295k
PRMOProm Resources Inc (PK)
US$ 0.000001
(-99.00%)
2.3M
CLISClickStream Corporation New (CE)
US$ 0.000001
(-99.00%)
1,000
SPRVSupurva Healthcare Group Inc (PK)
US$ 0.0001
(-50.00%)
443.5M
GRLFGreen Leaf Innovations Inc (PK)
US$ 0.0001
(9,900.00%)
106.59M
PDGOParadigm Oil and Gas Inc (PK)
US$ 0.0001
(-50.00%)
86.53M
RDARRaadr Inc (PK)
US$ 0.001
(-9.09%)
72.28M
HMBLHUMBL Inc (PK)
US$ 0.00075
(0.00%)
66.37M

MDNAF Discussion

Ver más
2H2 2H2 5 meses hace
Big conference next week. Paris.

Oui oui!
👍️0
2H2 2H2 5 meses hace
Bollies on daily are tightening up kids. Big conference coming up in sept
👍️0
2H2 2H2 6 meses hace
Research-Capital analyst- $MDNAF buy rating & $4.5 TP

MDNA11 continue to demonstrate compelling efficacy:
2 patients #melanoma & #pancreatic treated with MDNA11 continue to demonstrate a complete response

Notably, both patients were previously treated with checkpoint inhibitors
👍️0
2H2 2H2 8 meses hace
And more awesome results. 20x bagger here soon? Pc needs a new top line therapy, guess who?
👍️0
2H2 2H2 9 meses hace
MDNAF is a presenter at ASCO. Huge news!
👍️0
2H2 2H2 10 meses hace
Great presentation at ASCO
👍️0
Monksdream Monksdream 11 meses hace
It is what they all say about stonks trading on Cromwell Coulson’s stonk market
👍️0
2H2 2H2 11 meses hace
Relishing soon. This will be 10x current value this year
👍️0
Monksdream Monksdream 11 meses hace
Delisted from Nasdaq
Gee, it sure is great to watch the price of a stock I bought at $400 a share advance to a 52=week high
👍️0
2H2 2H2 11 meses hace
Getting legs here. Train leaving.
👍️0
axelvento axelvento 1 año hace
Cash runway extended through multiple data readouts and into Q1 of calendar 2025

MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion of the ABILITY-1 Study including 100% and 70% reduction of target lesions in pancreatic and melanoma cancer patients, respectively

https://ir.medicenna.com/news-releases/news-release-details/medicenna-therapeutics-reports-second-quarter-fiscal-2024
👍️0
Renee Renee 1 año hace
MDNA changed to MDNAF. Delisted from the Nasdaq to the OTC.

https://otce.finra.org/otce/dailyList?viewType=Additions
👍️0
Monksdream Monksdream 1 año hace
MDNA new 52 week low
👍️0
Monksdream Monksdream 1 año hace
MDNA new 52 week low
👍️0
Monksdream Monksdream 1 año hace
MDNA NEW 52 week low
👍️0
Investopotia Investopotia 3 años hace
Medicenna Therapeutics $MDNA highlighted in Midas Letter/BioPub interview: Top Stocks to Buy Now? 3 Biotech Stocks for your Watchlist
👍️0
EagleD EagleD 4 años hace
Going much higher. Double digits in a few months
👍️0
EagleD EagleD 4 años hace
Nice after hours action, Just made 20,000. Yadda Yadda Yadda.

Nobody is here listening to me. THis one is going to be a beast tho
👍️0
EagleD EagleD 4 años hace
FDA meeting Tuesday. Seems like we'll know sometime in October the results
👍️0
EagleD EagleD 4 años hace
This is my largest holding -- ever. Lots of value to be unveiled here in the coming months.
👍️0
Renee Renee 4 años hace
MDNA moved from the OTC to the Nasdaq:

https://otce.finra.org/otce/dailyList?viewType=Deletions
👍️0
tykundegex tykundegex 6 años hace
Just stumbled onto this co.. was doing some research. Great interim results in their Phase2b! Encouraging grants in the past, and prestigious medical centers for their trials. I may nibble to create a starting position here.

I can't find any webinars or conf call recordings that the company has given, do you know if any exist?
👍️0
BioSpecialist BioSpecialist 7 años hace
Nice move yesterday ..

Small Phase 2b trial has huge chance to be successful because it was already successfull in prior studies so this stock like to be above $10 after phase 2 results in early Q1 . And that Management holding 15+ million shares of the 24.3 million shares outstanding makes me also optimistic .GL


MDNA55 is enrolling patients in a Phase 2b clinical trial for rGB at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGB, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment,


Medicenna Phase 2b trial using Brainlab technology
http://www.biotuesdays.com/briefs/2017/6/8/medicenna-phase-2b-trial-using-brainlab-technology

The current Phase 2b clinical trial plans to enroll 43 adult patients with rGB at leading brain cancer centers in the U.S.
👍️0

Su Consulta Reciente

Delayed Upgrade Clock